KOSDAQ-listed SCL Science was strong early on the 26th. Buying appears to be gathering on an analysis from the securities industry that cancer vaccine development based on an artificial intelligence (AI) platform is expected.
As of 9:31 a.m. that day, SCL Science was trading at 2,320 won, up 255 won (12.35%) from the previous session.
SCL Science, the only listed affiliate and intermediate holding company of Seoul Clinical Laboratories (SCL), engages in bio data, precision medicine, and cancer vaccine research and development (R&D).
Shin Min-su of Kiwoom Securities said, "SCL Science entered the cancer vaccine development business last September by acquiring a 60% equity stake in Pentamedix (now Neogenlogic) for about 1.6 billion won," adding, "It steadily invested and built the AI platform 'DeepNeo' to develop cancer vaccines."
This platform is a technology for discovering neoantigens, an anticancer vaccine algorithm that analyzes T cells and, for the first time in the world, analyzes B-cell reactivity. It is currently targeting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the start of clinical trials within 2027.
Shin said, "Only 43% of neoantigen vaccines predicted by existing AI actually elicited a T-cell immune response in the body," and "If you include antigens with high B-cell reactivity at 20% or more when making a vaccine, the probability of generating a meaningful immune response in patients after administration can increase by 4.72 times."